NBS - Cystic Fibrosis

A positive newborn screening (NBS) means the screening test detected signs that a baby might have a genetic or metabolic condition. It is not a diagnosis; further diagnostic tests are required to confirm or rule out the disorder. Positive results prompt urgent follow-up with the newborn’s pediatrician or a specialist for confirmatory testing, clinical evaluation, and early treatment or monitoring if needed.

An abnormal newborn screening (NBS) result means a baby’s screening test shows an out-of-range or positive finding that suggests risk for a genetic, metabolic, endocrine, or hemoglobin disorder. It is not a definitive diagnosis but indicates the need for urgent follow-up testing and specialist evaluation. Prompt confirmatory tests and early treatment, when needed, can prevent serious complications and improve outcomes.

The Newborn Blood Spot (NBS) test is a heel‑prick screening done 24–72 hours after birth, collecting small blood spots to detect serious but treatable conditions (for example metabolic, endocrine, hemoglobin disorders, and cystic fibrosis). Early detection enables prompt treatment to prevent disability or death. Many programs also include newborn hearing screening and pulse oximetry for critical congenital heart disease.

Newborn screening for cystic fibrosis is highly accurate: combined IRT/DNA approaches detect over 95% of affected infants, while IRT-only methods are less sensitive. Specificity is high but positive predictive value varies with population and method. False positives occur (especially with IRT alone); false negatives are uncommon (around 1–5%). A diagnostic sweat test confirms any positive screen.

Newborn bloodspot screening (NBS) for cystic fibrosis tests newborns shortly after birth using a heel‑prick blood sample. Initial screening measures immunoreactive trypsinogen (IRT) and may include DNA testing for common CFTR mutations; abnormal results prompt a diagnostic sweat chloride test. Early identification enables prompt specialist care, nutritional and respiratory interventions, and genetic counseling to improve growth, lung health, and long‑term outcomes.

When a newborn screening (NBS) result is positive, promptly inform the parents and arrange confirmatory diagnostic testing. Refer the baby immediately to the appropriate specialist (metabolic/genetics/pediatrics), begin any urgent treatment or diet as advised, and monitor clinically. Provide genetic counseling, repeat testing if needed, and set a clear follow-up plan. Prioritize rapid evaluation to prevent complications.